Roivant Sciences Ltd. — Director's Dealing 2021

Oct 1, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Roivant Sciences Ltd. (ROIV)
CIK: 0001635088
Period of Report: 2021-10-01

Reporting Person: Sumitomo Chemical Co., Ltd. (10% Owner)
Reporting Person: Dainippon Sumitomo Pharma Co Ltd (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares	86367360	Indirect

Footnotes

F1: Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon") directly owns 86,367,360 Common Shares. Sumitomo Dainippon is a 51.78% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo"). Sumitomo may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitomo Dainippon owns. Sumitomo disclaims beneficial ownership of such reported securities except to the extent of its pecuniary interest therein.